UCB is in San Diego for DIA-Global 2019 this week. Ahead of her presentation, Liz Roberts, our Global Public Policy Lead, shares insights from the industry perspective on clinical trial disclosure and data transparency, and what UCB is doing to keep patients at the center of our work in this space. For more, see Liz speak today, June 25, 2019 at 2:00 p.m. in room 4 (session #260).

From discovery to development to delivery, how we do business has been transformed and redesigned around the patient’s individual experience. At UCB, patients are at the heart of everything we do, inspiring us and driving the ways in which we research, develop, and study differentiated treatments for patients. For 18 years, UCB BioSciences has been in the Research Triangle Park (RTP) in North Carolina and is an integral part of UCB’s mission to bring differentiated medicines to patients.

Every day, UCB researchers come to work driven by a singular purpose – to create value for people living with severe disease. That’s because, across the world, patients depend on the important work of scientific research to find new medical innovations that will help them achieve their goals. From the “breakthrough” moments in discovery, development, and delivery, we are dedicated to finding solutions for the unmet needs of patients.

Wake County, NC teachers visiting for UCB’s annual SummerSTEM day. (L to R) Andrew Oliver, Bruce Mamel, Michelle Woods, Sarah Brown, Ken Whisler, Cherilyn Murray, Antwanna Pegues Simmons, and Laura Williford.

At UCB, we are committed to accelerating scientific discoveries by supporting innovation — leading to the discovery of new solutions that help patients achieve their goals. As part this commitment, we believe it is important to support STEM education in our local communities to help inspire the next generation of scientists.

A key underserved patient population is women of childbearing age managing chronic conditions. In honor of Mother’s Day, Aimee Frank, Senior Director of Communications at the American Gastroenterological Association (AGA), shares about the IBD Parenthood Project, an effort led by the AGA with support by UCB, to help address the misperceptions women with inflammatory bowel disease and their healthcare providers experience throughout family planning.

Earlier this week, researchers from across UCB met in Washington, D.C. for the PhRMA Researcher Fly-In. While on Capitol Hill, the UCB team visited the offices of Representatives Doug Collins, Lucy McBath, and David Price, and Senators Johnny Isakson, Richard Burr, and Thom Tillis and walked their staff through the 15-year journey (on average) of how a new medicine is discovered, developed, and delivered at UCB. Each researcher, representing a different part of the drug development process, shared their personal stories about why they’re motivated each day to continue to innovate for patients.

We believe our ability to continue to innovate and create value for patients now and in the future will increasingly depend on our positive contributions to environmental sustainability.

At UCB, we are inspired by patients and driven by science to deliver what patients value. We are committed to continuously working to advance science and embrace new knowledge — leading to the discovery of new solutions that help patients achieve their goals.

We’re excited to welcome the 2019 American Academy of Dermatology (AAD) meeting to Washington, D.C. this week. As AAD comes to town, we wanted to offer a few recommendations from our D.C. staff. UCB’s D.C. office focuses on public policy with colleagues in advocacy, policy, public affairs, and regulatory.

For International Rare Disease Day, our Global Head of the Rozimab Mission, Chris Clark, shares insights about how UCB is leveraging and growing our capabilities to deliver value for specific patient populations new to UCB. Read the full article on LinkedIn.